Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer

Chemotherapy plus trastuzumab is the standard first-line treatment for Human Epidermal Receptor 2-positive (HER2-positive) metastatic breast cancer. The aim of this international phase II trial was to determine the efficacy and safety profile of an oral chemotherapy doublet, oral vinorelbine plus ca...

Full description

Bibliographic Details
Main Authors: Chan, Arlene, Conte, P., Petruzelka, L., Tubiana-Mathieu, N., Ganju, V., Llombart, A., Espie, M., Majois, F., Gil, M., Vaissiere, N., Villanova, G.
Format: Journal Article
Published: 2013
Online Access:http://hdl.handle.net/20.500.11937/25013

Similar Items

Similar Items